TY - JOUR
T1 - Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies
AU - Monjazeb, Arta M.
AU - Kent, Michael S.
AU - Grossenbacher, Steven K.
AU - Mall, Christine
AU - Zamora, Anthony E.
AU - Mirsoian, Annie
AU - Chen, Mingyi
AU - Kol, Amir
AU - Shiao, Stephen L.
AU - Reddy, Abhinav
AU - Perks, Julian R.
AU - Culp, William T.N.
AU - Sparger, Ellen E.
AU - Canter, Robert J.
AU - Sckisel, Gail D.
AU - Murphy, William J.
N1 - Funding Information:
This study was supported by UC Davis CTSC K12 Scholar Program, NIH 2 KL2 RRO24144-06; American Cancer Society Institutional Research Grant, IRG-95-125-07; Amador Cancer Research Foundation; Christine and Helen Landgraf Award; and NIH R01 CA 095572, NIH R01 CA 072669, and NCI P30CA093373. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 American Association for Cancer Research.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Purpose: Previous studies demonstrate that intratumoral CpG immunotherapy in combination with radiotherapy acts as an in-situ vaccine inducing antitumor immune responses capable of eradicating systemic disease. Unfortunately, most patients fail to respond. We hypothesized that immunotherapy can paradoxically upregulate immunosuppressive pathways, a phenomenon we term "rebound immune suppression," limiting clinical responses. We further hypothesized that the immunosuppressive enzyme indolamine-2,3-dioxygenase (IDO) is a mechanism of rebound immune suppression and that IDO blockade would improve immunotherapy efficacy. Experimental Design: We examined the efficacy and immunologic effects of a novel triple therapy consisting of local radiotherapy, intratumoral CpG, and systemic IDO blockade in murine models and a pilot canine clinical trial. Results: In murine models, we observed marked increase in intratumoral IDO expression after treatment with radiotherapy CpG, or other immunotherapies. The addition of IDO blockade to radiotherapy + CpG decreased IDO activity, reduced tumor growth, and reduced immunosuppressive factors, such as regulatory T cells in the tumor microenvironment. This triple combination induced systemic antitumor effects, decreasing metastases, and improving survival in a CD8+ T-cell-dependent manner. We evaluated this novel triple therapy in a canine clinical trial, because spontaneous canine malignancies closely reflect human cancer. Mirroring our mouse studies, the therapy was well tolerated, reduced intratumoral immunosuppression, and induced robust systemic antitumor effects. Conclusions: These results suggest that IDO maintains immune suppression in the tumor after therapy, and IDO blockade promotes a local antitumor immune response with systemic consequences. The efficacy and limited toxicity of this strategy are attractive for clinical translation.
AB - Purpose: Previous studies demonstrate that intratumoral CpG immunotherapy in combination with radiotherapy acts as an in-situ vaccine inducing antitumor immune responses capable of eradicating systemic disease. Unfortunately, most patients fail to respond. We hypothesized that immunotherapy can paradoxically upregulate immunosuppressive pathways, a phenomenon we term "rebound immune suppression," limiting clinical responses. We further hypothesized that the immunosuppressive enzyme indolamine-2,3-dioxygenase (IDO) is a mechanism of rebound immune suppression and that IDO blockade would improve immunotherapy efficacy. Experimental Design: We examined the efficacy and immunologic effects of a novel triple therapy consisting of local radiotherapy, intratumoral CpG, and systemic IDO blockade in murine models and a pilot canine clinical trial. Results: In murine models, we observed marked increase in intratumoral IDO expression after treatment with radiotherapy CpG, or other immunotherapies. The addition of IDO blockade to radiotherapy + CpG decreased IDO activity, reduced tumor growth, and reduced immunosuppressive factors, such as regulatory T cells in the tumor microenvironment. This triple combination induced systemic antitumor effects, decreasing metastases, and improving survival in a CD8+ T-cell-dependent manner. We evaluated this novel triple therapy in a canine clinical trial, because spontaneous canine malignancies closely reflect human cancer. Mirroring our mouse studies, the therapy was well tolerated, reduced intratumoral immunosuppression, and induced robust systemic antitumor effects. Conclusions: These results suggest that IDO maintains immune suppression in the tumor after therapy, and IDO blockade promotes a local antitumor immune response with systemic consequences. The efficacy and limited toxicity of this strategy are attractive for clinical translation.
UR - http://www.scopus.com/inward/record.url?scp=84988584598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988584598&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-3026
DO - 10.1158/1078-0432.CCR-15-3026
M3 - Article
C2 - 26979392
AN - SCOPUS:84988584598
SN - 1078-0432
VL - 22
SP - 4328
EP - 4340
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -